Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab.
We describe an immunocompetent 19-year-old man with CD20-positive primary central nervous system (CNS) lymphoma refractory to chemotherapy and irradiation. After intraventricular administration of rituximab, a chimeric anti-CD20 monoclonal antibody, supplemented with autologous serum, a remarkable response developed to the CNS parenchymal lymphoma. Cytotoxicity assays showed that untreated patient's serum with rituximab, but not that of heat-inactivated patient's serum with rituximab or rituximab alone, induced potent rituximab-mediated cytotoxicity against tumor cells in the patient's cerebrospinal fluid, suggesting induction of complement-dependent cytotoxicity against CNS lymphoma.
Takami
Akiyoshi
A
Department of Cellular Transplantation Biology, Kanazawa Univeristy Graduate School of Medicine, Kanazawa 920-8641, Japan. takami@med3.m.kanazawa-u.ac.jp
Hayashi
Tomoe
T
Kita
Daisuke
D
Nishimura
Ryosei
R
Asakura
Hidesaku
H
Nakao
Shinji
S
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D002460:Cell Line; D016543:Central Nervous System Neoplasms / Q000134:cerebrospinal fluid / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D003165:Complement System Proteins / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D007276:Injections, Intraventricular; D008223:Lymphoma / Q000134:cerebrospinal fluid / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D008297:Male; D000069283:Rituximab; D044967:Serum; D015898:Tomography Scanners, X-Ray Computed
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D003165:Complement System Proteins